Recurrent Glioblastoma
Given the aggressive nature of glioblastoma, it is nearly a certainty that all patients will need to be evaluated for potential treatment of recurrent disease. There is currently no definitive…
Lessons Learned: Clinical Trials and Other Interventions for Glioblastoma
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and accounts for 16% of all primary brain tumors and for 45% of malignant primary brain tumors. Despite…
National and Global Economic Impact of Glioblastoma
Introduction The cost of cancer treatment has progressively increased over the past decade as newer chemotherapy and immunotherapy agents have been established. Glioblastoma, in particular, has a significant cost in…
Tumor-Treating Electric Fields for Glioblastoma
Acknowledgments The authors acknowledge and thank Kisa Zhang for her artwork in Fig. 17.1 . Historical context of electric field treatment The application of physical energy from various parts of the…
Health-related Quality of Life and Neurocognitive Functioning After Glioblastoma Treatment
Introduction With a median survival of 12 to 14 months, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. Treatment is therefore not only designed to prolong survival but also…
Socioeconomics and Survival
Introduction Accounting for 52% of all primary brain tumors, glioblastoma is the most common and most aggressive. Glioblastomas account for 20% of all intracranial tumors. Disparities in risk factors, incidence,…
Brain Plasticity and Reorganization Before, During, and After Glioma Resection
Introduction The traditional principle in neuro-oncology is to study the tumor first, with little consideration regarding the host; that is, the brain. Nevertheless, to define the optimal therapeutic management for…
General Principles of Immunotherapy for Glioblastoma
Background Despite trimodal therapy consisting of maximal safe resection and adjuvant partial radiotherapy with concurrent and subsequent temozolomide, glioblastoma (GBM) has a dismal prognosis, with a median survival of 14.6 months…
Early Detection of Glioblastoma
Historical context and biological basis Early detection of solid tumors is vital for extending survival and possibly curing patients with cancer. This idea is especially relevant to patients with the most…
Intraoperative Imaging of Glioblastoma
Introduction Glioblastoma (GBM) is one of the deadliest forms of cancer, with a median survival of approximately 15 months. Standard of care treatment of GBM includes maximal safe surgical resection, fractionated…
